These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 5429106)

  • 1. Miosis during L-dopa therapy.
    Spiers AS; Calne DB; Fayers PM
    Br Med J; 1970 Jun; 2(5710):639-40. PubMed ID: 5429106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-dopa, Parkinson's disease and pupillary reaction to light.
    Knopp W; Rotenberg M; Boye R
    Monogr Hum Genet; 1972; 6():198. PubMed ID: 4577119
    [No Abstract]   [Full Text] [Related]  

  • 3. Action of dopamine on the human iris.
    Spiers AS; Calne DB
    Br Med J; 1969 Nov; 4(5679):333-5. PubMed ID: 5386267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotension caused by L-dopa.
    Calne DB; Brennan J; Spiers AS; Stern GM
    Br Med J; 1970 Feb; 1(5694):474-5. PubMed ID: 4907812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-3,4-dihydroxyphenylalanine-induced of norepinephrine from the rat heart.
    Landsberg L
    Biochem Pharmacol; 1971 Dec; 20(12):3542-7. PubMed ID: 5132898
    [No Abstract]   [Full Text] [Related]  

  • 6. Pupillary effects of levodopa therapy. Development of anisocoria in latent Horner's syndrome.
    Weintraub MI; Gaasterland D; Van Woert MH
    N Engl J Med; 1970 Jul; 283(3):120-3. PubMed ID: 5423148
    [No Abstract]   [Full Text] [Related]  

  • 7. Mydriatic responses to sympathomimetic amines in patients treated with L-dopa.
    Godwin-Austen RB; Lind NA; Turner P
    Lancet; 1969 Nov; 2(7629):1043-4. PubMed ID: 4187547
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa and anticholinergic drugs in Parkinsonism.
    Burn JH
    Br Med J; 1971 Jun; 2(5764):773-4. PubMed ID: 5090790
    [No Abstract]   [Full Text] [Related]  

  • 9. The action of reserpine on noradrenaline biosynthesis in sympathetic nerve tissue.
    Roth RH; Stone EA
    Biochem Pharmacol; 1968 Aug; 17(8):1581-90. PubMed ID: 5672819
    [No Abstract]   [Full Text] [Related]  

  • 10. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD
    Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483
    [No Abstract]   [Full Text] [Related]  

  • 12. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxic delirium after L-dopa medication.
    Birkmayer W
    J Neural Transm Suppl; 1978; (14):163-6. PubMed ID: 290736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of L-dopa on postural reflexes in Parkinson's disease.
    Chaco J; Abramsky O
    Z Neurol; 1971; 200(2):122-5. PubMed ID: 4108115
    [No Abstract]   [Full Text] [Related]  

  • 15. False neurotransmitters and hepatic failure.
    Fischer JE; Baldessarini RJ
    Lancet; 1971 Jul; 2(7715):75-80. PubMed ID: 4103986
    [No Abstract]   [Full Text] [Related]  

  • 16. Cerebral catecholamine concentration after L-dopa therapy in Parkinson's disease.
    Greer M; Anton AH
    Trans Am Neurol Assoc; 1970; 95():247-8. PubMed ID: 4328099
    [No Abstract]   [Full Text] [Related]  

  • 17. Action of thymoxamine on mydriasis induced by levodopa and dopamine.
    Spiers AS; Calne DB; Vakil SD; French TM
    Br Med J; 1971 May; 2(5759):438-9. PubMed ID: 4396960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gamma-Aminobutyric acid reduces the evoked release of [3H]-noradrenaline from sympathetic nerve terminals [proceedings].
    Bowery NG; Hudson AL
    Br J Pharmacol; 1979 May; 66(1):108P. PubMed ID: 454903
    [No Abstract]   [Full Text] [Related]  

  • 19. [Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].
    Dupont E
    Ugeskr Laeger; 1973 Jan; 135(3):116-22. PubMed ID: 4567942
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.